TherapeuticsMD (TXMD, Financial), a pharmaceutical company focusing on women’s health, detracted in the quarter as revenues grew more slowly than expected. The company continued to grow, however, and we believe the market undervalues the revenue potential of its assets.
From First Eagle Investment (Trades, Portfolio)'s Fund of America fourth-quarter 2019 commentary.